LennardMS, TuckerGT, WoodsHF. Inborn “errors” of drug metabolism; pharmacokinetics and clinical implications. Clin Pharmacokinet1990; 19:257–63.
2.
EvansWE, RellingMV, PetrosWPDextromethorphan and caffeine as probes for simultaneous determination of debrisoquine oxidation and N-acetylation phenotypes in children. Clin Pharmacol Ther1989; 45:568–73.
3.
RamsayLE, SilasJH, OllerenshawJDShould the acetylator phenotype be determined when prescribing hydralazine for hypertension. Eur J Clin Pharmacol1984; 26:39–42.
4.
RahavG, Zylber-KatzE, RachmilewitzDRelationship between the acetylator phenotype, plasma sulfapyridine levels and advese effects during treatment with salicylazosulfapyridine in patients with chronic bowel diseases. Isr J Med Sci1990; 26:31–4.
5.
GrantDM, MorikeK, EichelbaumMAcetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver. J Clin Invest1990; 85:968–72.
6.
RiederMJ, ShearNH, KaneeAProminence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions. Clin Pharmacol1991; 49:13–7.
7.
RiederMJ, UetrechtJ, ShearNHDiagnosis of sulfonamide hypersensitivity reactions by in vitro “rechallenge” with hydroxylamine metabolites. Ann Intern Med1989; 110:286–9.
8.
WeinshilboumR.Pharmacogenetics of methylation: relationship to drug metabolism. Clin Biochem1988; 21:201–10.
9.
LennardL, Van LoonJA, LilleymanJSThiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations. Clin Pharmacol Ther1987; 41:18–25.
10.
LennardL, LilleymanJS. Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. J Clin Oncol1989; 7:1816–23.
11.
LennardL, Van LoonJA, WeinshilboumRM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther1989; 46:149–54.
WaringRH, SteventonGB, SturmanSG. S-Methylation in motoneuron disease and Parkinson's disease. Lancet1989; 2:356–7.
14.
ReillyDK, Rivera-CalimlimL, Van DykeD. Catechol O-methyltransferase activity: a determinant of levodopa response. Clin Pharmacol Ther1980; 28:278–86.
15.
CampbellNRC, DunnetteJH, MwalukoGPlatelet phenol sulfotransferase and erythrocyte catechol O-methyltransferase activities: correlation with methyldopa metabolism in man. Clin Pharmacol Ther1984; 35:55–63.
16.
BrosenK.Recent developments in hepatic drug oxidation; implications for clinical pharmacokinetics. Clin Pharmacokinet1990; 18:220–39.
17.
GuengerichFP. Characterization of human microsomal cytochrome P450 enzymes. Arm Rev Pharmacol Toxicol1989; 29:241–64.
18.
GonzalezFJ. Molecular genetics of the P450 superfamily. Pharmacol Ther1990; 45:1–38.
19.
HouZ-Y, PickleLW, MeyerPSSalivary analysis for determination of dextromethorphan metabolic phenotype. Clin Pharmacol Ther1991; 49:410–9.
20.
LennardMS. Genetic polymorphism of sparteine/debrisoquine oxidation: a reappraisal. Pharmacol Toxicol1990; 67:273–83.
21.
JacksonPR, TuckerGT. Pharmacokinetic-pharmacogenetic modelling in the detection of polymorphism in xenobiotic metabolism. Ann Occup Hyg1990; 34:653–62.
22.
AyeshR, DawlingS, HaylerAComparative effects of the diastereoisomers, quinine and quinidine in producing phenocopy debrisoquine poor metabolisers (PMs) in healthy volunteers. Chirality1991; 3:14–8.
23.
HeimM, MeyerUA. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet1990; 336:529–32.
24.
DayerP, DesmeulesJ, LeemannTBioactivauon of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation. Biochem Biophys Res Commun1988; 152:411–6.
DesmeulesHW, DayerP, GasconM-PImpact of genetic and environmental factors on codeine analgesia (abstract). Clin Pharmacol Ther1989; 45:122.
27.
MikusG, GrossAS, BeckmannRThe influence of the sparteine/debrisoquine phenotype on the disposition of flecainide. Clin Pharmacol Ther1989; 45:562–7.
28.
GrossAS, MikusG, FischerCPolymorphic flecainide disposition under conditions of uncontrolled urine flow and pH. Eur J Clin Pharmacol1991; 40:155–62.
29.
LennardMS. The polymorphic oxidation of beta-adrenoceptor antagonists. Pharmacol Ther1989; 41:461–77.
30.
JonkersRE, KoopmansRP, PortierEJGDebrisoquine phenotype and the pharmacokinetics and beta-2 receptor pharmacodynamics of metoprolol and its enantiomers. J Pharmacol Exp Ther1991; 256:959–66.
31.
BrosenK, ZeuginT, MeyerUA. Role of P450IID6, the target of the sparteine-debrisoquin oxidation polymorphism, in the metabolism of imipramine. Clin Pharmacol Ther1991; 49:609–17.
32.
Dahl-PuustinenML, JohanssonI, Ingelman-SundbergMDisposition of perphenazine is related to polymorphic debrisoquine hydroxylation. Clin Pharmacol Ther1989; 46:78–81.
33.
TyndaleRF, KalowW, InabaT.Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (sparteine/debrisoquine monooxygenase). Br J Clin Pharmacol1991; 31:655–60.
34.
von BahrC, MovinG, NordinCPlasma levels of thioridazine and metabolites are influenced by the debrisoquine hydroxylation phenotype. Clin Pharmacol Ther1991; 49:234–40.
